MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
8.43
-0.10
-1.17%
After Hours: 8.48 +0.05 +0.59% 19:57 06/13 EDT
OPEN
8.54
PREV CLOSE
8.53
HIGH
8.80
LOW
8.13
VOLUME
6.87M
TURNOVER
0
52 WEEK HIGH
18.33
52 WEEK LOW
3.210
MARKET CAP
2.36B
P/E (TTM)
-4.6418
1D
5D
1M
3M
1Y
5Y
Interesting IOVA Put And Call Options For December 20th
NASDAQ · 3d ago
Weekly Report: what happened at IOVA last week (0603-0607)?
Weekly Report · 4d ago
IOVA Quantitative Stock Analysis - Benjamin Graham
NASDAQ · 06/04 18:03
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Iovance Biotherapeutics (IOVA) and Immunocore Holdings (IMCR)
TipRanks · 06/04 08:21
Iovance Biotherp: Current report
Press release · 06/03 12:15
Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 11:49
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Benzinga · 06/03 11:39
Piper Sandler Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
TipRanks · 06/03 10:56
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.